HealthCare Global Enterprises Limited announced that its board of directors has unanimously approved a significant rights issue during their meeting held on February 17, 2026. The healthcare company's board approved the issuance of fully paid-up equity shares worth up to ₹42,500 lakh, marking a major capital raising initiative for the organization. The rights issue will offer fully paid-up equity shares with a face value of ₹10 each to eligible equity shareholders as on the record date. The board meeting commenced at 5:00 PM and concluded at 7:25 PM on February 17, 2026, following the company's prior intimation dated February 8, 2026. The board has delegated authority to the Rights Issue Committee of the Board of Directors to determine specific and detailed terms of the rights issue, including issue price determination, rights entitlement ratio, record date specification, timing of the rights issue, and terms of payment. The company will meet on February 24, 2026 to finalize details of the ₹425 crore rights issue, including price, entitlement ratio, and record date, as reported by The News Strike.
While the immediate focus is on the rights issue, HCG's financial health has been a subject of ongoing scrutiny. In the fiscal year ending March 2024, the company reported revenues of ₹19,079 million, representing a healthy 12.8% increase year-on-year. Its net profit saw a substantial jump of 134.5% YoY to ₹413 million, with net profit margins improving to 2.2% from 1.0% in the previous year. However, recent quarterly results have shown mixed performance, with reports indicating a net loss of ₹9.43 crores and negative net profit margin of -1.48% for Q3 FY25-26, while another report stated a net profit of ₹3.24 crores with a significant 53.58% YoY decline.
The company's balance sheet carries a notable debt burden, with net debt rising to ₹1,601 crores as of March 31, 2025, up from ₹1,001.75 crores the previous year, driven by capital expenditure and acquisitions. The company's debt-to-equity ratio stands at approximately 177.9%, considered high according to analysis, and has increased over the past five years. This elevated leverage leads to a low interest coverage ratio of 1.4 times by EBIT, indicating a limited cushion to service interest expenses. Despite efforts to improve profitability with EBITDA margins hovering around 17-18%, the rising debt levels and recent quarterly losses present significant financial challenges. The company has approved raising authorized share capital from ₹20 crore to ₹22 crore and adopted updated Articles of Association under the Companies Act, 2013, to support future expansion and proposed preferential allotment, enhancing financial flexibility.
In September of the previous year, Aceso Company, part of the CVC Network, sold nearly 6% stake in HealthCare Global Enterprises via a block deal on the NSE, raising ₹552 crore at an average price of ₹695 per share. According to CNBC TV18, of the 79 lakh shares sold, Nippon India Mutual Fund bought 44 lakh shares worth ₹306 crore, increasing its stake by 3.2% on top of the 2.5% it already held as of June 2025. Other significant buyers included Plutus Wealth Management (₹50 crore), Axis Mutual Fund (₹66 crore), and Morgan Stanley Asia Singapore (₹61 crore).
Shares of Healthcare Global Enterprises Ltd ended at ₹578.60, down by ₹5.80, or 0.99%, on the BSE today, February 17, according to CNBC TV18. The stock's performance reflects market reaction to the company's rights issue announcement. The planned rights issue is expected to help strengthen the balance sheet, potentially by reducing debt or funding future expansion, with the company planning to add approximately 900 incremental beds over the next 4 to 5 years. However, recent analyst reports have highlighted concerns about deteriorating quality metrics and financial performance, leading to downgrades for the stock, while high promoter share pledging at 85.23% as of February 2026 remains a risk factor for investors.
